Scinai Immunotherapeutics (NASDAQ:SCNI) Announces Quarterly Earnings Results

Posted by Dante Gardener on Aug 26th, 2026

Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.74) earnings per share for the quarter, Zacks reports. The business had revenue of $0.46 million during the quarter.

Scinai Immunotherapeutics Price Performance

SCNI stock opened at $2.88 on Wednesday. The stock’s 50 day moving average is $2.64 and its two-hundred day moving average is $4.94. Scinai Immunotherapeutics has a 52-week low of $2.15 and a 52-week high of $16.80. The company has a market capitalization of $1.50 million, a PE ratio of -2.72 and a beta of 2.08. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.05.

Institutional Trading of Scinai Immunotherapeutics

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC boosted its stake in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) by 146.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. 58.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

View Our Latest Research Report on Scinai Immunotherapeutics

Scinai Immunotherapeutics Company Profile

(Get Free Report)

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.